Evidence map›Paper›PMID 21719769›Full record

Trial reportStroke2011

Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence.

Joseph P Broderick, Jordan B Bonomo, Brett M Kissela, Jane C Khoury, Charles J Moomaw, Kathleen Alwell, Daniel Woo, Matthew L Flaherty, Pooja Khatri, Opeolu Adeoye and 2 more

4 registry-linked trialsAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Stroke, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04684212 nawithdrawnnot on this mapstarted 2024, after this paper: background citation

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study

TypeinterventionalSponsorBrian O'Neill MDRan2024 to 2024Enrolled0ConditionsAtrial Fibrillation, Left Atrial Appendage Thrombosis, CVAArmsLAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
NCT06465706 nanot yet recruitingnot on this mapstarted 2024, after this paper: background citation

A Prospective, Multicenter, Randomized Controlled Trial Assessing the Safety and Efficacy of the LAmbre™ Plus Left Atrial Appendage Closure System to REDUCE the Risk of Thromboembolism in Patients With Non-Valvular Atrial Fibrillation

TypeinterventionalSponsorKansas City Heart Rhythm Research FoundationRan2024 to 2030Enrolled1,826ConditionsAtrial FibrillationArmsLAmbre investigational device
NCT06844227 recruitingnot on this mapstarted 2021, after this paper: background citation

Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual), a Simple Perioperative Anticoagulant Management Approach, Replacing a Resource-intensive In-person Doctor-patient Consultation, With a Simple Virtual Care Model That Will Provide a New Standard of Care for Patients on a Direct Oral Anticoagulant or Warfarin and Require Elective Surgery/Procedure.

TypeobservationalSponsorMcMaster UniversityRan2021 to 2026Enrolled1,780ConditionsAtrial Fibrillation (AF)
NCT06957366 narecruitingnot on this mapstarted 2025, after this paper: background citation

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure: A Randomized Control Trial

TypeinterventionalSponsorMcMaster UniversityRan2025 to 2027Enrolled920ConditionsAtrial Fibrillation (AF), VTEArmsPAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. The safety and feasibility of anticoagulant resumption following middle meningeal artery embolization in patients with subacute subdural hematomas.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding.European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joseph P BroderickUniversity of Cincinnati, Department of Neurology, University of Cincinnati Neuroscience Institute, University of Cincinnati Academic Health Center MSB #0525, Cincinnati, OH 45242, USA. joseph.broderick@uc.edu
Jordan B Bonomo
Brett M Kissela
Jane C Khoury
Charles J Moomaw
Kathleen Alwell
Daniel Woo
Matthew L Flaherty
Pooja Khatri
Opeolu Adeoye
Simona Ferioli
Dawn O Kleindorfer

Funding

STROKE INCIDENCE AND OUTCOME AMONG BLACKS AND WHITESR01NS030678 · NINDS · UNIVERSITY OF CINCINNATI · PI KISSELA, BRETT M, KLEINDORFER, DAWN O · 1993 to 2024
$26.7M
Cerebrovascular Fellowship Training ProgramT32NS047996 · NINDS · UNIVERSITY OF CINCINNATI · PI Joseph Paul Broderick, Stacie Demel · 2006 to 2026
$3.7M
NINDS NIH HHS R01 NS030678NINDS NIH HHS R01NS30678NINDS NIH HHS T32 NS047996
6 · The paper itself

Abstract

background and purposeAntithrombotic medications (anticoagulants and antiplatelets) are often withheld in the periprocedural period and after bleeding complications to limit the risk of new or recurrent bleeding. These medications are also stopped by patients for various reasons such as cost, side effects, or unwillingness to take medication.

methodsPatient records from the population-based Greater Cincinnati/Northern Kentucky Stroke Study were reviewed to identify cases of ischemic stroke in 2005 and determine the temporal association of strokes with withdrawal of antithrombotic medication. Ischemic strokes and reasons for medication withdrawal were identified by study nurses for subsequent physician review.

resultsIn 2005, 2197 cases of ischemic stroke among residents of the region were identified through hospital discharge records. Of the 2197 ischemic strokes, 114 (5.2%) occurred within 60 days of an antithrombotic medication withdrawal, 61 (53.5%) of these after stoppage of warfarin and the remainder after stoppage of an antiplatelet medication. Of the strokes after withdrawal, 71 (62.3%) were first-ever and 43 (37.7%) were recurrent; 54 (47.4%) occurred after withdrawal of medication by a physician in the periprocedural period.

conclusionsThe withdrawal of antiplatelet and antithrombotic medications in the 60 days preceding an acute ischemic stroke was associated with 5.2% of ischemic strokes in our study population. This finding emphasizes the need for thoughtful decision-making concerning antithrombotic medication use in the periprocedural period and efforts to improve patient compliance.

Indexed as

Brain IschemiaPatient ComplianceStrokeWithholding TreatmentAgedFibrinolytic AgentsHumansKentuckyMaleOhioRetrospective StudiesTime FactorsWarfarinFibrinolytic AgentsWarfarin

Identifiers

PMID21719769
PMCPMC3166233

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.